Introduction
============

Ovarian cancer (OC), which frequently occurs in postmenopausal women ([@b1-mmr-18-03-3289]), is a cancer with no apparent symptoms until it reaches an advanced stage. The symptoms include bloating, abdominal swelling, pelvic pain and loss of appetite ([@b2-mmr-18-03-3289]). The three most common OC subtypes are high-grade serous carcinomas, sex cord stromal tumors and germ cell tumors ([@b3-mmr-18-03-3289]), which may metastasize to the peritoneum, liver, lungs or lymph nodes ([@b4-mmr-18-03-3289]). OC is difficult to detect and metastasizes early in disease progression; therefore, patients with OC frequently have a poor prognosis ([@b5-mmr-18-03-3289]). Globally, OC affects 1.2 million women and led to 161,100 mortalities in 2015 ([@b6-mmr-18-03-3289],[@b7-mmr-18-03-3289]). Thus, obtaining an improved understanding of OC progression and recurrence is of great importance for improving its prognosis.

Previously, genes affecting OC were identified, including p21-activated kinase 4 (*Pak4*), cyclin E1 (*CCNE1*), RNA binding motif protein 3 (*RBM3*), YY1 associated protein 1 (*YAP*) and prominin-1 (*CD133*). *Pak4* overexpression has been reported to contribute to OC cell migration, invasion and proliferation, thus making it a promising prognostic indicator and therapeutic target ([@b8-mmr-18-03-3289]). *CCNE1* amplification has been demonstrated to markedly reduce disease-free survival and overall survival, thus indicating that *CCNE1*-targeted treatment may benefit patients with OC who have upregulated *CCNE1* expression ([@b9-mmr-18-03-3289],[@b10-mmr-18-03-3289]). In epithelial ovarian cancer, *RBM3* expression has been associated with cisplatin sensitivity and correlated with a positive patient prognosis ([@b11-mmr-18-03-3289]). Furthermore, *YAP* has been associated with cell growth and tumorigenesis, and its coexpression with TEA domain transcription factor 4 serves as a predictor of a poor outcome ([@b12-mmr-18-03-3289],[@b13-mmr-18-03-3289]). CD133 also serves as a predictor of poor OC patient survival, thus suggesting that it may serve as a biomarker of cancer stem cells during disease ([@b14-mmr-18-03-3289]). However, the further identification of prognostic indicators and their potential uses is required.

In recent years, bioinformatics analysis of expression profile data has been gradually used to examine the pathogenesis of human diseases ([@b15-mmr-18-03-3289]). It is known that the progress of a disease is usually mediated by multiple relevant genes and not by a single gene ([@b16-mmr-18-03-3289],[@b17-mmr-18-03-3289]). Therefore, the present study was designed to mine subnetwork features and build a model to assess OC recurrence risk. In the present study, OC expression profiles were downloaded from a public database, and differentially expressed genes (DEGs) were analyzed and functionally enriched. Following identification of a functional subnetwork, a random forest classifier was constructed and validated. It was considered that this constructed classifier may provide an improved approach for predicting the prognoses of patients with OC.

Materials and methods
=====================

### Data source

RNA sequence data from 307 OC samples and their corresponding clinical data (including patient vital status and overall survival) were downloaded from The Cancer Genome Atlas (TCGA; <http://cancergenome.nih.gov>) database. Based on patient vital status, 180 recurrent samples and 72 disease-free samples were identified. Additionally, the GSE44104 dataset \[including 20 recurrent and 40 non-recurrent OC samples; platform, (HG-U133_Plus_2) Affymetrix Human Genome U133 Plus 2.0 Array, Affymetrix; Thermo Fisher Scientific, Inc., Waltham, MA, USA\] and the GSE49997 dataset (including 204 OC samples; platform, GPL2986 ABI Human Genome Survey Microarray version 2, Applied Biosystems; Thermo Fisher Scientific, Inc.) were obtained from the Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo>) database and utilized as validation sets.

### Data preprocessing and DEG screening

Using a z-score algorithm ([@b18-mmr-18-03-3289]), the expression value of each gene was normalized to a normal distribution (mean=0; variance=1). The samples were subsequently analyzed using the differential expression via distance synthesis (DEDS) algorithm, which may be applied to obtain differential expression levels via the distance synthesis of relevant data ([@b19-mmr-18-03-3289]). This approach was used to screen DEGs in the recurrent samples relative to the disease-free samples.

### Functional enrichment analysis

Gene ontology (GO; <http://www.geneontology.org>) analysis may be used to predict the potential functions of gene products ([@b20-mmr-18-03-3289]). Using GO Term Finder (<http://search.cpan.org/dist/GO-TermFinder/>) as previously described ([@b21-mmr-18-03-3289]), upregulated and downregulated genes were separately enriched. Functional terms with P\<0.05 and an association with at least three genes were selected as significant terms.

### Weighted gene coexpression network analysis (WGCNA)

Genes may jointly influence alterations in functional terms through their interactions, with functional consistencies between genes also confirmed by significant expression level correlations. To systematically analyze how DEGs with similar expression profiles co-affect OC prognosis, WGCNA ([@b22-mmr-18-03-3289]) was performed. Based on the obtained weighted gene coexpression levels, DEG coexpression was suggested to be significantly associated with OC prognosis. To further identify the genes that were able to differentiate between patients with OC with different prognoses, the verified DEG protein-protein interaction (PPI) pairs were used to construct a PPI network using BioNet 1.24.1 package (<http://www.bioconductor.org/packages/release/bioc/html/BioNet.html>).

### Subnetwork analysis and classifier construction

The BioNet package (<http://bionet.bioapps.biozentrum.uni-wuerzburg.de>) provides an extensive framework that enables functional subnetworks to be isolated from biological networks. Using the BioNet package in R 3.1.0 ([@b23-mmr-18-03-3289]), as previously described ([@b24-mmr-18-03-3289]), subnetwork analysis was conducted for the PPI network with the P-value/false discovery rate set to 0.01. With the subnetwork nodes as feature genes, a random forest classifier ([@b25-mmr-18-03-3289]) was constructed. For sample labels (recurrence/no recurrence), true and false positive rates were calculated and combined with leave-one-out cross validation ([@b26-mmr-18-03-3289]). Additionally, a receiver operating characteristic (ROC) curve was constructed ([@b27-mmr-18-03-3289]) to evaluate the classification efficiency of the random forest classifier.

Validation using other independent datasets. To confirm that the subnetwork nodes were able to effectively differentiate between patients with OC with different prognoses, the classification efficiency of the random forest classifier for the validation set (GSE44104) was analyzed and presented using a confusion matrix. Additionally, a Kaplan-Meier (KM) survival analysis ([@b28-mmr-18-03-3289]) was performed and combined with the clinical information belonging to the TCGA dataset.

Results
=======

### DEG screening

Following implementation of the DEDS algorithm, a total of 44 upregulated and 117 downregulated genes were identified in the recurrent samples relative to the non-recurrent samples, with more downregulated genes identified compared with upregulated genes. Additionally, a volcano plot was constructed to examine DEG expression distributions ([Fig. 1](#f1-mmr-18-03-3289){ref-type="fig"}).

### Functional enrichment analysis

Using the GO Term Finder, significant GO terms were enriched for the upregulated and downregulated genes separately. For the upregulated genes, the enriched GO terms were primarily associated with the 'regulation of synapse assembly' (P=1.04×10^−7^), 'regulation of synapse organization' (P=5.26×10^−7^), and 'regulation of synapse structure or activity' (P=5.71×10^−7^; [Table IA](#tI-mmr-18-03-3289){ref-type="table"}). The downregulated genes were associated with 'single-multicellular organism process' (P=4.11×10^−5^), 'multicellular organismal process' (P=5.14×10^−5^) and 'positive regulation of steroid hormone biosynthetic process' (P=3.83×10^−3^; [Table IB](#tI-mmr-18-03-3289){ref-type="table"}), which included cytochrome P450 family 17 subfamily A member 1 (*CYP17A1*).

### WGCNA

WGCNA was performed and turquoise and grey modules were identified within the cluster dendrogram ([Fig. 2](#f2-mmr-18-03-3289){ref-type="fig"}). Within the turquoise module, 87 genes were identified (14 upregulated and 73 downregulated), while in the grey module, 74 were identified (30 upregulated and 44 downregulated). Correlations between the two modules regarding status/prognosis were also analyzed. The results demonstrated that the two modules had significant correlations with status and prognosis (P\<0.05; [Fig. 3](#f3-mmr-18-03-3289){ref-type="fig"}). Furthermore, sample correlations were further examined via heatmap analysis, and it was indicated that the samples in the turquoise module were more strongly correlated when compared with those in the grey module ([Fig. 4](#f4-mmr-18-03-3289){ref-type="fig"}).

### Subnetwork analysis and classifier construction

Following building of the PPI network, subnetwork analysis was performed and a significant subnetwork was identified ([Fig. 5](#f5-mmr-18-03-3289){ref-type="fig"}). The importance scores for the 16 subnetwork nodes \[transcription factor GATA-4 (GATA4); fibroblast growth factor 9 (FGF9); aromatase (CYP19A1); 3β-hydroxysteroid dehydrogenase/δ5-4-isomerase type 2 (HSD3B2); corticosteroid 11β-dehydrogenase isozyme 1 (HSD11B1); CYP17A1; pituitary homeobox 2 (PITX2); left-right determination factor 1 (LEFTY1); homeobox protein ARX (ARX); estrogen receptor β (ESR2); steroidogenic factor 1 (NR5A1); forkhead box protein L2 (FOXL2); myocardin (MYOCD); steroidogenic acute regulatory protein mitochondrial (STAR); vesicular inhibitory amino acid transporter (SLC32A1); and twist-related protein 1 (TWIST1)\] are listed in [Table II](#tII-mmr-18-03-3289){ref-type="table"}. There were multiple interactions among these subnetwork nodes, including HSD3B2-NR5A1, HSD11B1-HSD3B2, CYP17A1-GATA4, ARX-FOXL2, MYOCD-GATA4, STAR-FGF9 and SLC32A1-PITX2. The subnetwork nodes were taken as feature genes and a random forest classifier was constructed. The generated ROC curve demonstrated that the true and false positive rates separately were 92 and 23% when classifying the recurrent and non-recurrent OC samples ([Fig. 6A](#f6-mmr-18-03-3289){ref-type="fig"}).

### Validation using other independent datasets

The random forest classifier was used to differentiate between samples in the GSE44104 validation set, and the prediction accuracies for the non-recurrence and recurrence groups were 87.5 and 85%, respectively ([Fig. 6B](#f6-mmr-18-03-3289){ref-type="fig"}). These findings indicated that the subnetwork nodes were important in predicting OC prognosis.

Of the 307 OC samples in the TCGA dataset, only 262 samples remained upon removal of samples without follow-up or survival time information. These 262 samples were divided into high- and low-risk groups using the random forest classifier, and further examined using KM survival analysis. The results demonstrated that the low risk group had a significantly longer survival time compared with the high-risk group (P=0.0166; [Fig. 7A](#f7-mmr-18-03-3289){ref-type="fig"}). Subsequently, the samples from the second validation set (GSE49997) were divided into high- and low-risk groups using the random forest classifier. Following analysis using a KM survival curve, a significant difference was noted in survival time between the low- and high-risk groups (P=0.0165; [Fig. 7B](#f7-mmr-18-03-3289){ref-type="fig"}). These findings suggested that the random forest classifier had portability and repeatability.

Discussion
==========

In the present study, 44 upregulated and 117 downregulated genes were identified in the recurrent samples relative to the non-recurrent samples. When performing WGCNA, turquoise and grey modules were identified that had significant correlations with status and prognosis. Furthermore, a significant subnetwork was identified from the PPI network, with the subnetwork nodes (including GATA4, FGF9, CYP19A1, HSD3B2, HSD11B1, CYP17A1, PITX2, LEFTY1, ARX, ESR2, NR5A1, FOXL2, MYOCD, STAR, SLC32A1 and TWIST1) being utilized as feature genes for constructing a random forest classifier. Moreover, the classification efficiency of the random forest classifier was validated and confirmed.

Of the identified nodes, previous studies have reported that *GATA4* overexpression, in conjunction with human epidermal growth factor receptor 2, may predict a shorter disease-free survival time and may be utilized as a prognostic marker in patients with ovarian granulosa cell tumor to optimize follow-up management in the early stages ([@b29-mmr-18-03-3289],[@b30-mmr-18-03-3289]). In OC, *GATA4* and transcription factor GATA-6 expression is frequently lost, with this feature specifying the histological subtype prior to tumorigenic transition of the ovarian surface epithelium ([@b31-mmr-18-03-3289]). The upregulation of *FGF9* has been detected in primary ovarian endometrioid adenocarcinomas carrying a defective Wnt/β-catenin pathway and serves an important role in promoting the cancer phenotype ([@b32-mmr-18-03-3289],[@b33-mmr-18-03-3289]). The aromatase enzyme encoded by the *CYP19A1* gene acts in the conversion of androgen to estrogen, with *CYP19A1* variants potentially able to influence OC susceptibility ([@b34-mmr-18-03-3289]). Thus, GATA4, *FGF9* and *CYP19A1* appear to be implicated in the mechanisms of OC pathogenesis. Enrichment analysis demonstrated that *CYP17A1*, which is involved in 'positive regulation of steroid hormone biosynthetic processes', was downregulated. A previous study demonstrated that steroid hormones serve a role in OC pathogenesis, and their receptors influence OC patient survival ([@b35-mmr-18-03-3289]). Therefore, *CYP17A1* may affect OC patient prognoses through the positive regulation of steroid hormones.

The overexpression of *PITX2* has been implicated in OC progression by facilitating cell growth, migration and invasion, and thus may potentially serve as a therapeutic target for patients with high-grade OC ([@b36-mmr-18-03-3289],[@b37-mmr-18-03-3289]). *PITX2* has also been demonstrated to promote OC cell proliferation through the Wnt pathway, which is closely associated with ovarian development and OC ([@b38-mmr-18-03-3289]). In ovarian clear cell carcinoma, the overexpression of *LEFTY*, a transforming growth factor-β superfamily member, exhibits an anti-tumor effect by affecting cell proliferation and cellular susceptibility to apoptotic signals ([@b39-mmr-18-03-3289]). Estrogen receptor β, which is encoded by the *ESR2* gene, has been suggested to serve as a critical factor during OC carcinogenesis ([@b40-mmr-18-03-3289]). Furthermore, within the *ESR2* promoter region, the genotypic and allelic frequencies of the single nucleotide polymorphism (SNP) rs3020449 have been demonstrated to exhibit significant differences based on OC stage, thus indicating that SNP rs3020449 may be associated with OC progression ([@b41-mmr-18-03-3289]). These findings suggest that *PITX2, LEFTY1* and *ESR2* may also serve roles in OC pathogenesis.

*NR5A1* serves an important role in ovarian function and development, with an *NR5A1* mutation reported to induce 46 XY disorders of sex development ([@b42-mmr-18-03-3289]). *FOXL2* is critical for GC (granulosa cell) differentiation during the process of folliculogenesis, with its downregulation potentially serving as an ovarian granulosa cells tumor prognostic factor ([@b43-mmr-18-03-3289]). *TWIST1*, which may induce epithelial-mesenchymal transition and contribute to tumor metastasis, has been demonstrated to be associated with poor survival in patients with cancer ([@b44-mmr-18-03-3289],[@b45-mmr-18-03-3289]). Thus, *NR5A1, FOXL2* and *TWIST1* may be associated with patient survival in OC. Moreover, the multiple interactions within the PPI subnetwork (including HSD3B2-NR5A1, HSD11B1-HSD3B2, CYP17A1-GATA4, ARX-FOXL2, MYOCD-GATA4, STAR-FGF9 and SLC32A1-PITX2) indicate that *HSD3B2, HSD11B1, CYP17A1, ARX, MYOCD, STAR* and *SLC32A1* may also function in OC by interacting with other genes.

However, the present study has several limitations to note. First, the datasets used in the present study had sample size differences, platform differences and data heterogeneities that may affect the prediction accuracy of the random forest classifier. Second, the smaller patient numbers and analytical methods may limit the predictive capability of the present model. Finally, only bioinformatics analyses were conducted in the present study, and no direct experimental validation was performed. Therefore, further analyses are required to validate the obtained results.

In conclusion, 44 upregulated and 117 downregulated genes associated with OC recurrence were identified. Furthermore, the 16 subnetwork node genes that were identified may be critical molecules associated with OC recurrence.
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![Volcano plot illustrating differentially expressed gene expression distributions. Upregulated genes are depicted in red and downregulated in green.](MMR-18-03-3289-g00){#f1-mmr-18-03-3289}

![Weighted gene coexpression network analysis cluster dendrogram. Grey means grey module identified in WGCNA with 30 upregulated and 44 downregulated; turquoise means turquoise module identified in WGCNA with 14 upregulated and 73 downregulated genes. WGCNA, Weighted gene coexpression network analysis.](MMR-18-03-3289-g01){#f2-mmr-18-03-3289}

![Module-trait relationship graph illustrating that turquoise and grey modules have significant correlations with status/prognosis. Red color indicates a positive correlation, while green means a negative correlation. Grey means grey module identified in WGCNA with 30 upregulated and 44 downregulated; turquoise means turquoise module identified in WGCNA with 14 upregulated and 73 downregulated genes.](MMR-18-03-3289-g02){#f3-mmr-18-03-3289}

![Heatmap displaying gene correlations for the turquoise and grey modules. A deeper color indicates a stronger correlation, while a lighter color suggests a weaker correlation. Grey means grey module identified in WGCNA; turquoise means turquoise module identified in WGCNA. WGCNA, Weighted gene coexpression network analysis.](MMR-18-03-3289-g03){#f4-mmr-18-03-3289}

![Significant subnetwork identified within the protein-protein interaction network. Upregulated genes are denoted in red and downregulated in green. GATA4, transcription factor GATA-4; FGF9, fibroblast growth factor 9; CYP19A1, aromatase; HSD3B2, 3β-hydroxysteroid dehydrogenase/δ5-4-isomerase type 2; HSD11B1, corticosteroid 11β-dehydrogenase isozyme 1; CYP17A1, cytochrome P450 family 17 subfamily A member 1; PITX2, pituitary homeobox 2; LEFTY1, left-right determination factor 1; ARX, homeobox protein ARX; ESR2, estrogen receptor β; NR5A1, steroidogenic factor 1; FOXL2, forkhead box protein L2; MYOCD, myocardin; STAR, steroidogenic acute regulatory protein mitochondrial; SLC32A1, vesicular inhibitory amino acid transporter; TWIST1, twist-related protein 1.](MMR-18-03-3289-g04){#f5-mmr-18-03-3289}

![ROC curve analysis. ROC curves for the (A) Cancer Genome Atlas and (B) GSE44104 datasets. FPR, false positive rate; TPR, true positive rate; AUC, area under the curve; ROC, receiver operating characteristic.](MMR-18-03-3289-g05){#f6-mmr-18-03-3289}

![KM survival analysis. KM survival curves for the (A) Cancer Genome Atlas and (B) GSE49997 datasets. Predicted high risk (cluster 1) groups are indicated in red and low risk (cluster 2) groups in black. KM, Kaplan-Meier.](MMR-18-03-3289-g06){#f7-mmr-18-03-3289}

###### 

Significant functional terms enriched for the upregulated and downregulated genes.

  A, Upregulated genes                                                                              
  ------------------------------------------------------------- ----------------------- ----------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Regulation of synapse assembly                                1.04×10^−7^             5           *DKK1, LINGO2, TPBG, SLITRK5, SLITRK3*
  regulation of synapse organization                            5.26×10^−7^             5           *DKK1, LINGO2, TPBG, SLITRK5, SLITRK3*
  regulation of synapse structure or activity                   5.71×10^−7^             5           *DKK1, LINGO2, TPBG, SLITRK5, SLITRK3*
  synapse assembly                                              2.08×10^−6^             5           *DKK1, LINGO2, TPBG, SLITRK5, SLITRK3*
  positive regulation of synapse assembly                       6.78×10^−6^             4           *LINGO2, TPBG, SLITRK5, SLITRK3*
  synapse organization                                          2.23×10^−5^             5           *DKK1, LINGO2, TPBG, SLITRK5, SLITRK3*
  regulation of nervous system development                      2.72×10^−4^             6           *LRRC7, DKK1, LINGO2, TPBG, SLITRK5, SLITRK3*
  positive regulation of nervous system development             4.44×10^−4^             5           *LRRC7, LINGO2, TPBG, SLITRK5, SLITRK3*
  regulation of developmental process                           1.131×10^−3^            8           *LRRC7, DKK1, SLITRK3, BVES, LINGO2, MEGF10, SLITRK5, TPBG*
  regulation of multicellular organismal development            1.96×10^−3^             7           *LRRC7, DKK1, LINGO2, MEGF10, TPBG, SLITRK5, SLITRK3*
  positive regulation of developmental process                  2.64×10^−3^             6           *LRRC7, DKK1, LINGO2, TPBG, SLITRK5, SLITRK3*
  system development                                            2.84×10^−3^             10          *LRRC7, DKK1, SLITRK3, WDR69, BVES, C8orf85, LINGO2, MEGF10, TPBG, SLITRK5*
  regulation of multicellular organismal process                3.63×10^−3^             8           *LRRC7, DKK1, SLITRK3, BVES, LINGO2, MEGF10, SLITRK5, TPBG*
  single-organism developmental process                         5.75×10^−3^             11          *LRRC7, DKK1, SLITRK3, WDR69, BVES, C8orf85, LINGO2, MEGF10, MMP7, TPBG, SLITRK5*
  developmental process                                         6.65×10^−3^             11          *LRRC7, DKK1, SLITRK3, WDR69, BVES, C8orf85, LINGO2, MEGF10, MMP7, TPBG, SLITRK5*
  single-multicellular organism process                         8.10×10^−3^             11          *LRRC7, DKK1, SLITRK3, WDR69, BVES, C8orf85, LINGO2, MEGF10, MMP7, TPBG, SLITRK5*
  positive regulation of multicellular organismal process       8.16×10^−3^             6           *LRRC7, DKK1, LINGO2, TPBG, SLITRK5, SLITRK3*
  multicellular organism development                            9.65×10^−3^             10          *LRRC7, DKK1, SLITRK3, WDR69, BVES, C8orf85, LINGO2, MEGF10, TPBG, SLITRK5*
  regulation of cellular component biogenesis                   9.92×10^−3^             5           *DKK1, LINGO2, TPBG, SLITRK5, SLITRK3*
                                                                                                    
  **B, Downregulated genes**                                                                        
                                                                                                    
  **Terms**                                                     **Corrected P-value**   **Count**   **Genes**
                                                                                                    
  single-multicellular organism process                         4.11×10^−5^             23          *GJA8, TRIM71, TCF23, FOXL2, SCNN1G, CPNE5, ARX, CACNA2D2, SLC32A1, AQP5, CCR4, SPTB, HOXC5, RD3, FGF9, PDZD7, PROK1, IL33, WNT6, CYP17A1, BMP6, LGI1, COLEC11*
  multicellular organismal process                              5.14×10^−5^             25          *GJA8, TRIM71, TCF23, FOXL2, SCNN1G, CPNE5, ARX, CACNA2D2, SLC32A1, AQP5, CCR4, TAS1R3, SPTB, HOXC5, RD3, FGF9, PDZD7, PROK1, IL33, WNT6, ACCN3, CYP17A1, BMP6, LGI1, COLEC11*
  eye development                                               5.32×10^−5^             7           *RD3, GJA8, FGF9, BMP6, AQP5, FOXL2, WNT6*
  sensory organ development                                     7.88×10^−5^             8           *RD3, GJA8, FGF9, BMP6, PDZD7, AQP5, FOXL2, WNT6*
  multicellular organism development                            1.86×10^−4^             20          *GJA8, TRIM71, TCF23, FOXL2, CPNE5, ARX, SLC32A1, AQP5, CCR4, SPTB, HOXC5, FGF9, RD3, PDZD7, PROK1, WNT6, CYP17A1, BMP6, LGI1, COLEC11*
  anatomical structure development                              1.87×10^−4^             21          *GJA8, TRIM71, TCF23, FOXL2, CPNE5, ARX, CACNA2D2, SLC32A1, AQP5, CCR4, SPTB, HOXC5, FGF9, RD3, PDZD7, PROK1, WNT6, CYP17A1, BMP6, LGI1, COLEC11*
  single-organism developmental process                         5.26×10^−4^             21          *GJA8, TRIM71, TCF23, FOXL2, CPNE5, ARX, CACNA2D2, SLC32A1, AQP5, CCR4, SPTB, HOXC5, FGF9, RD3, PDZD7, PROK1, WNT6, CYP17A1, BMP6, LGI1, COLEC11*
  system development                                            5.74×10^−4^             18          *GJA8, TRIM71, TCF23, FOXL2, CPNE5, ARX, SLC32A1, AQP5, CCR4, SPTB, FGF9, RD3, PDZD7, PROK1, WNT6, CYP17A1, BMP6, LGI1*
  developmental process                                         6.76×10^−4^             21          *GJA8, TRIM71, TCF23, FOXL2, CPNE5, ARX, CACNA2D2, SLC32A1, AQP5, CCR4, SPTB, HOXC5, FGF9, RD3, PDZD7, PROK1, WNT6, CYP17A1, BMP6, LGI1, COLEC11*
  positive regulation of steroid hormone biosynthetic process   3.83×10^−3^             2           *BMP6, CYP17A1*
  positive regulation of growth                                 4.05×10^−3^             5           *CACNA2D2, FGF9, LGI1, CPNE5, ARX*
  nervous system development                                    4.48×10^−3^             12          *FGF9, PDZD7, TRIM71, WNT6, CPNE5, CYP17A1, ARX, BMP6, LGI1, SLC32A1, CCR4, SPTB*
  positive regulation of organ growth                           7.93×10^−3^             3           *CACNA2D2, FGF9, ARX*
  camera-type eye development                                   8.92×10^−3^             5           *RD3, GJA8, AQP5, FOXL2, WNT6*
  anatomical structure morphogenesis                            9.15×10^−3^             12          *FGF9, PROK1, PDZD7, TRIM71, FOXL2, WNT6, CPNE5, ARX, BMP6, LGI1, AQP5, SPTB*

###### 

Importance scores of the subnetwork nodes.

  Node      Score
  --------- --------
  ARX       15.203
  CYP17A1   10.956
  CYP19A1   10.902
  ESR2      10.537
  FGF9      10.148
  FOXL2     9.827
  GATA4     9.786
  HSD11B1   9.223
  HSD3B2    9.196
  LEFTY1    8.259
  MYOCD     7.867
  NR5A1     7.634
  SLC32A1   6.367
  STAR      6.167
  PITX2     5.094
  TWIST1    4.708

GATA4, transcription factor GATA-4; FGF9, fibroblast growth factor 9; CYP19A1, aromatase; HSD3B2, 3β-hydroxysteroid dehydrogenase/δ5-4-isomerase type 2; HSD11B1, corticosteroid 11β-dehydrogenase isozyme 1; CYP17A1, cytochrome P450 family 17 subfamily A member 1; PITX2, pituitary homeobox 2; LEFTY1, left-right determination factor 1; ARX, homeobox protein ARX; ESR2, estrogen receptor β; NR5A1, steroidogenic factor 1; FOXL2, forkhead box protein L2; MYOCD, myocardin; STAR, steroidogenic acute regulatory protein mitochondrial; SLC32A1, vesicular inhibitory amino acid transporter; TWIST1, twist-related protein 1.
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